Explore our top cGMP-compliant research and commercial Grade APIs engineered to satisfy stringent international regulatory mandates.
Understanding the strategic necessity of N1-Methylpseudouridine (m1Ψ) in suppressing innate immune activation while maximizing protein expression efficiency.
In the rapidly evolving landscape of synthetic biology and nucleoside chemistry, N1-Methylpseudouridine-5'-Triphosphate (m1Ψ) has established itself as the single most vital modified nucleotide for messenger RNA (mRNA) platforms. Following the breakthrough recognition of nucleoside base modifications in therapeutic RNA, substituting unmodified Uridine with m1Ψ significantly decreases Toll-Like Receptor (TLR7 and TLR8) activation and RIG-I recognition. This structural modification prevents intracellular RNA-sensing pathways from triggering unwanted inflammatory responses, extending mRNA half-life and boosting translation yield by up to 10-fold compared to conventional transcripts.
As global biopharmaceutical firms expand beyond viral infectious disease vaccines into oncology (personalized cancer vaccines), gene editing (CRISPR-Cas mRNA delivery), and protein replacement therapies, the demand for bulk OEM Methyl Pseudouridine has skyrocketed. Procurement teams require strict batch-to-batch reproducibility, ultra-low endotoxin levels (<0.01 EU/mg), complete absence of RNase activity, and robust security of supply. Enterprise buyers need CDMO partners capable of supporting transitions seamlessly from benchtop R&D synthesis to multikilogram commercial supply.
Our cGMP production protocols guarantee rigorous validation, complete characterization, and analytical transparency for every lot produced.
| Analytical Parameter | OEM Standard Specification | Testing Methodology | Quality Impact |
|---|---|---|---|
| Chemical Purity | ≥ 99.5% (HPLC Peak Area) | RP-HPLC / Ion-Exchange HPLC | Eliminates truncation fragments & improper IVT transcripts |
| Nucleoside Identification | Conforms to Structure Standard | 1H-NMR / 31P-NMR / LC-MS | Ensures precise molecular structure and methylation site |
| Bacterial Endotoxins | < 0.01 EU/mg (Ultrapure Grade) | LAL Kinetic Chromogenic Method | Prevents pyrogenic immune response in downstream therapeutics |
| RNase / DNase Contamination | None Detected (N.D.) | Fluorescence-Based Nuclease Assays | Guarantees mRNA structural integrity during IVT transcription |
| Residual Solvents | Meets ICH Q3C Requirements | Headspace Gas Chromatography (GC-MS) | Ensures toxicological safety for clinical trial filings |
| Heavy Metals Concentration | < 5 ppm Total Heavy Metals | ICP-MS Analysis | Prevents metal-catalyzed hydrolysis of synthesized RNA |
Empowering biopharmaceutical innovators with end-to-end custom synthesis, formulation assistance, and global procurement infrastructure.
Our raw m1Ψ NTP reagents are tailored specifically for high-yield IVT reactions driven by T7, T3, or SP6 RNA polymerases. With customized concentration formulations, optimized salt profiles, and enzyme-compatible buffers, we minimize abortive transcripts and optimize full-length mRNA generation.
Whether developing targeted oncology neoantigen vaccines, prophylactic viral vaccines, or localized protein expression therapeutics, our OEM custom packaging supports seamless scaling from laboratory screening to industrial scale-up.
Alongside nucleosides, we provide specialized CDMO services for peptide APIs, non-natural amino acid synthesis, and Finished Dosage Form (FDF) licensing out. Our infrastructure allows integrated supply chains for multi-modal biologics.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions. An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
International standard facilities engineered for scalability and cost efficiency.
Comprehensive sourcing to avoid the complexity of multiple vendor contacts.
Global Compliance & Operational Certifications
Pioneering green synthesis, high-throughput biotransformation, and ultra-pure nucleotide architecture for modern genomic medicine.
Transitioning from traditional organic chemical synthesis to multi-enzyme cascade biotransformation. This pathway eliminates toxic heavy metal catalysts, lowers residual organic solvents to zero, and achieves stereospecific C-glycosidic bond formation with absolute purity.
Implementing microfluidic continuous-flow reactors for commercial m1Ψ and capping analog manufacturing. Flow chemistry guarantees inline analytical monitoring (PAT), precise temperature control, and instant reaction quenching, drastically cutting batch-to-batch variability.
Expanding OEM offerings to include double-modified nucleosides (e.g., 2'-O-methylated and phosphorothioate-linked NTPs) designed for enhanced oral or aerosolized mRNA therapeutics and organ-specific lipid nanoparticle target optimization.
Streamlining international drug filings with complete DMF documentation, regional representative offices, and robust supply chain risk mitigation.
Navigating regulatory approvals requires comprehensive structural and analytical validation. We provide full Drug Master File (DMF) support, Type II DMF filings with the US FDA, CEP filings for European markets, and structural stability data under ICH guidelines (Q1A to Q1F). Our dedicated regulatory team facilitates rapid access for clients entering IND (Investigative New Drug) and NDA (New Drug Application) stages.
To eliminate international transit risks and ensure uncompromised product integrity, Gentolex operates regional representative hubs in Mexico and South Africa alongside global distribution centers. All modified nucleosides and peptides are dispatched in validated cold-chain packaging (-20°C to -80°C temperature monitoring), backed by dual-sourcing redundancies.
Deep technical answers regarding OEM Methyl Pseudouridine synthesis, quality validation, and commercial procurement.
Stay up to date with Gentolex's cutting-edge scientific research articles and technical progress across therapeutic peptide APIs.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed through neuropharmacological research, Selank represents a key advancement...
View Details
As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and life science teams worldwide...
View Details
BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, and inflammatory regulation...
View Details
With continuous development in neuroscience and peptide technology, neuroactive peptides have become a pivotal research frontier. Semax, derived from an ACTH fragment, exhibits high stability and distinct neuroprotective properties...
View Details
SS-31 API, also known as Elamipretide, MTP-131, and Bendavia, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, supporting bioenergetics and stabilization...
View DetailsFrom organic synthesis building blocks to specialized pharmaceutical intermediates, browse our trusted global inventory.
